Related Links
Current Releases
Stock Quote
Standard & Poor's
SEC Filings
Mailing List
Releases Archives
Opexa Therapeutics Headlines
09/11/2008 - 07:30 AM
Top-Line Data from Opexa's Phase IIb Tovaxin(R) Study to be Presented at World Congress on Treatment and Research in Multiple Sclerosis
09/03/2008 - 07:30 AM
Opexa Therapeutics and Myelin Repair Foundation Partner on Novel Multiple Sclerosis Research Program
08/14/2008 - 07:30 AM
Opexa Therapeutics Reports Second Quarter 2008 Financial Results and Recent Corporate Highlights
08/13/2008 - 07:30 AM
Opexa Therapeutics Completes $3 Million Financing
07/22/2008 - 08:00 AM
Opexa Conducts Additional Analysis on Phase I/II Extension Study with Tovaxin(R) for Multiple Sclerosis
07/08/2008 - 08:00 AM
Opexa's Phase IIb Study of Tovaxin(R) Receives Positive Review from Data Safety Monitoring Board
06/17/2008 - 08:00 AM
Opexa Therapeutics Appoints Neil K. Warma President and CEO
06/16/2008 - 08:00 AM
Opexa Therapeutics Presents Monocyte-Derived Islet Cell Research at the International Society for Stem Cell Research Annual Meeting
06/12/2008 - 08:00 AM
Opexa Therapeutics Reports Favorable Two-Year Data in Phase I/II Retreatment Studies of Tovaxin(R) for Multiple Sclerosis
05/22/2008 - 09:00 AM
Opexa Therapeutics Presents Myelin Reactive T-Cell Research at the International Society of Cell Therapy Annual Meeting
05/14/2008 - 03:30 PM
Opexa Therapeutics Schedules First Quarter Results Conference Call; May 21, 2008 at 4:00 p.m. Eastern Time
05/13/2008 - 04:00 PM
Opexa Therapeutics Reports First Quarter 2008 Financial Results and Updates on Tovaxin(R) Phase IIb Study
04/15/2008 - 03:30 PM
Opexa Therapeutics Presents Tovaxin Phase I/II Data at the American Academy of Neurology 60th Annual Meeting
03/26/2008 - 04:59 PM
Opexa Therapeutics' Form 10-K Report Audit Includes ''Going Concern'' Qualification
03/24/2008 - 08:00 AM
Opexa Therapeutics to Present at the Cambria Capital Investor Meeting
03/21/2008 - 09:00 AM
Opexa Therapeutics Announces Retirement of CEO David McWilliams
03/18/2008 - 08:00 AM
Opexa Therapeutics Reports Year End 2007 Financial Results
03/11/2008 - 07:00 AM
Opexa Therapeutics Announces Completion of Mid Study Descriptive Analysis on Phase IIb Trial of Tovaxin(R) for Treatment of Multiple Sclerosis
02/19/2008 - 12:14 PM
Opexa Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Series E Warrants
02/13/2008 - 04:35 PM
Opexa Therapeutics Announces the Pricing of Public Offering of Shares of Common Stock and Series E Warrants
11/16/2007 - 03:59 PM
Opexa Therapeutics' Amendment No.1 on Form 10-KSB/A Report Audit Includes ''Going Concern'' Qualification
11/05/2007 - 09:35 AM
Opexa Reports Third Quarter 2007 Financial Results
10/05/2007 - 12:42 PM
Opexa Therapeutics to Present at the BIO Investor Forum 2007
09/26/2007 - 07:30 AM
Opexa Therapeutics Appoints Dr. Dawn McGuire, Prominent Neurologist, to Multiple Sclerosis Clinical Advisory Board
09/20/2007 - 07:00 AM
Opexa Appoints Lorin J. Randall to Board of Directors
1
2
3
4
5
« Previous
Next »
Releases Archives
